← Back to Analyst Consensus 
CMMB Buy
Chemomab Therapeutics Ltd.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 18, 2026 (23 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 27, 2025 | Oppenheimer | maintain | Outperform → Outperform | $25 | 52% |
| May 16, 2025 | Oppenheimer | maintain | Outperform → Outperform | $10 | 52% |
| Feb 20, 2025 | Maxim Group | maintain | Buy → Buy | $7 | 42% |
| Nov 15, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $11 | 52% |
| May 13, 2024 | Maxim Group | initiate | — → Buy | $4 | 42% |
| May 6, 2024 | Oppenheimer | upgrade | Perform → Outperform | $6 | 52% |
| Mar 8, 2024 | Oppenheimer | maintain | Perform → Perform | $0 | 52% |
| Oct 6, 2023 | Roth MKM | initiate | — → Buy | $7 | 52% |
| Jun 7, 2023 | Oppenheimer | downgrade | Outperform → Perform | $0 | 52% |
| Apr 18, 2023 | Oppenheimer | maintain | — → Outperform | $7 | 52% |
| Mar 10, 2022 | Oppenheimer | maintain | — → Outperform | $20 | 52% |
| Dec 7, 2021 | Aegis Capital | initiate | — → Buy | $30 | — |
| May 26, 2021 | Cantor Fitzgerald | initiate | — → Overweight | $45 | 50% |
| May 7, 2021 | Oppenheimer | initiate | — → Outperform | $42 | 52% |
Price Target Trend
Jun 13, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days